Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop (2025)
Chapter: Appendix B: Workshop Agenda
Visit
NAP.edu/10766
to get more information about this book, to buy it in print, or to
download it as a free PDF.
Previous Chapter:
Appendix A: References
Appendix B
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Appendix B
Workshop Agenda
EXAMINING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1R) AGONISTS FOR CENTRAL NERVOUS SYSTEM DISORDERS
The Keck Center, 500 Fifth Street NW
Washington, DC 20001
TUESDAY, SEPTEMBER 10, 2024
ROOM 100
| 9:00–9:05 | Introductory Remarks Frances Jensen, University of Pennsylvania, Co-chair, Forum on Neuroscience and Nervous System Disorders Deanna Barch, University of Washington in St. Louis, Co-chair, Forum on Neuroscience and Nervous System Disorders |
| 9:05–9:10 | Workshop Overview Matthew Hayes, University of Pennsylvania, Workshop Co-chair Brian Fiske, Michael J. Fox Foundation for Parkinson’s Research, Workshop Co-chair |
| 9:10–9:25 | Keynote Presentation: History of GLP-1Rs and Current Therapeutic Applications Daniel Drucker, University of Toronto (Zoom) |
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
| 9:25–9:45 | Overview of GLP-1 Circuitry in the Central Nervous System Linda Rinaman, Florida State University, Planning Committee Member Anna Secher, Novo Nordisk (Zoom) |
| 9:45–10:05 | Moderated Panel and Audience Q&A |
SESSION 1—CLINICAL EFFICACY AND MECHANISMS OF ACTION OF GLP-1R AGONISTS IN CENTRAL NERVOUS SYSTEMS
- Review the current state of knowledge regarding the mechanisms of action of GLP-1R agonists and their therapeutic applications across different disease areas.
- Discuss available scientific evidence on the clinical efficacy of GLP-1R agonists, among other considerations, for treating various central nervous system disorders, including eating disorders, neurodegenerative diseases, and alcohol and substance use disorders.
- Consider the unique challenges (e.g., stigma, health disparities, clinical trial design, biomarker development) for each disease area.
Session 1a: Ingestive Behavior Disorders
| 10:05–10:10 | Session Overview Kimberlei Richardson, Howard University, Session Moderator, Planning Committee Member |
| 10:10–10:20 | A Lived Experience Utilizing GLP-1R Agonists Patricia Nece, Obesity Action Coalition |
| 10:20–10:45 | Speaker Presentations Jon Davis, Novo Nordisk, Planning Committee Member Elizabeth Mietlicki-Baase, University of Buffalo Susan McElroy, University of Cincinnati (Zoom) |
| 10:45–11:10 | Moderated Panel and Audience Q&A |
| 11:10–11:25 | BREAK |
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Session 1b: Substance Use Disorder and Alcohol Use Disorder
| 11:25–11:30 | Session Overview Lorenzo Leggio, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Session Moderator, Planning Committee Member |
| 11:30–12:10 | Speaker Presentations Elisabet Jerlhag, University of Gothenburg, Planning Committee Member (Zoom) Heath Schmidt, University of Pennsylvania Mehdi Farokhnia, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism Rong Xu, Case Western Reserve Patricia (Sue) Grigson, Penn State University |
| 12:10–12:35 | Moderated Panel and Audience Q&A |
| 12:35–1:15 | LUNCH BREAK |
Topic 1c: Neurodegenerative Disorders and Other Emerging Areas
| 1:15–1:20 | Session Overview Edwin (Ted) George, Food and Drug Administration, Session Moderator, Planning Committee Member |
| 1:20–1:50 | Speaker Presentations Nigel Greig, National Institute on Aging Dilan Athauda, University College London and Francis Crick Institute Christian Hölscher, Kariya Pharmaceuticals Alexandra Sinclair, University of Birmingham |
| 1:50–2:00 | Biomarker Development for Clinical Evidence and Regulatory Approval Laura Jawidzik, Food and Drug Administration |
| 2:00–2:25 | Moderated Panel and Audience Q&A |
| 2:25–2:40 | BREAK |
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
SESSION 2—REAL-WORLD EVIDENCE, ACCESSIBILITY, AND HEALTH EQUITY
- Consider the role of real-world evidence for the repurposing of GLP-1R agonist in CNS disorders.
- Evaluate the impact of widespread usage of GLP-1R agonists on patient and public accessibility and the supply chain.
- Consider future challenges and opportunities to improve health equity for the use of GLP-1R in different therapeutic areas.
| 2:40–2:45 | Session Overview Serena Jingchuan Guo, University of Florida, Session Moderator, Planning Committee Member |
| 2:45–2:50 | A Lived Experience Perspective on Accessibility and Equity Karen Glanz, University of Pennsylvania |
| 2:50-3:10 | Speaker Remarks Jiang Bian, University of Florida Robert Kosko, Food and Drug Administration (Zoom) Fatima Cody Stanford, Massachusetts General Hospital and Harvard Medical School |
| 3:10–3:50 | Moderated Panel and Audience Q&A |
SESSION 3—SYNTHESIS & OPPORTUNITIES TO MOVE FORWARD
- Examine the core themes that have been highlighted during the workshop.
- Highlight current research gaps and consider opportunities to move the field forward.
| 3:50–3:55 | Session Overview Matthew Hayes, University of Pennsylvania, Workshop Co-chair Brian Fiske, Michael J. Fox Foundation for Parkinson’s Research, Workshop Co-chair |
| 3:55–4:25 | Themes and Future Opportunities Discussion Matthew Coghlan, Eli Lilly and Company, Planning Committee Member Karen Glanz, University of Pennsylvania |
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
| Serena Jingchuan Guo, University of Florida, Planning Committee Member Iván Montoya, National Institute on Drug Abuse, Planning Committee Member Patricia Nece, Obesity Action Coalition |
|
| 4:25–4:30 | Concluding Remarks Matthew Hayes, University of Pennsylvania, Workshop Co-chair Brian Fiske, Michael J. Fox Foundation for Parkinson’s Research, Workshop Co-chair |
| 4:30 | Adjourn Workshop |
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
This page intentionally left blank.
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Suggested Citation:
"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
doi: 10.17226/29061.
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.